AdAlta is pleased to welcome Mr Fadi Diab as a Non-executive Director of the Board. Mr Diab is an experienced ASX director who brings significant investor relations and market analysis skills to AdAlta’s Board.

AdAlta’s Chair, Dr Paul MacLeman said:

“We are pleased to welcome Fadi Diab to our Board. AdAlta is advancing multiple growth and value realisation opportunities across its “East to West” cellular immunotherapy strategy and existing i-body® enabled assets as well as new opportunities being presented to it. Fadi’s investor relations, communications and market analytics capabilities and connections will be invaluable as we navigate these opportunities.”